Uterine fibroid

NESA MEDTECH RECEIVES U.S. FDA CLEARANCE FOR ITS FIBROID MAPPING REVIEWER APPLICATION (FMRA)

Retrieved on: 
Monday, July 24, 2023
Diving at the 2014 Commonwealth Games – Women's 1 metre springboard, Pelvic pain, Nesa, Obstetrics, Leiomyoma, Quality of life, Infertility, Uterus, MD, Physician, Patient, Growth hormone therapy, Uterine fibroid, Fibroid, Gynaecology, Diagnosis, Hospital, Department of Obstetrics and Gynecology (Massachusetts General Hospital), FDA, Massachusetts General Hospital, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Medical imaging

BENGALURU, India, July 24, 2023 /PRNewswire/ -- Nesa Medtech (Nesa), a private medical device company addressing clinical unmet needs for patients with symptomatic uterine fibroids, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's Fibroid Mapping Reviewer Application (FMRA). The technology is intended for use by physicians to generate a 3D model of the uterus from ultrasound images to assist in the accurate diagnosis and planning of interventional procedures for patients with uterine fibroids.

Key Points: 
  • BENGALURU, India, July 24, 2023 /PRNewswire/ -- Nesa Medtech (Nesa), a private medical device company addressing clinical unmet needs for patients with symptomatic uterine fibroids, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's Fibroid Mapping Reviewer Application (FMRA).
  • "Receiving FDA clearance is a significant milestone and a proud moment for the company," said Sreekar Kothamachu, CEO.
  • "Nesa's FMRA technology allows physicians to determine fibroid location and dimensions, critical details for effective minimally invasive image guided treatment planning."
  • "Receiving FDA clearance is a significant milestone and a proud moment for the company," said Sreekar Kothamachu, CEO of Nesa Medtech.

Health in Her HUE to Host Discussion Around Fibroids Awareness and Launch the Fibroids-focused Care Squad Program during Fibroid Awareness Month

Retrieved on: 
Monday, June 26, 2023
Survivor, Endometriosis, Partnership, Boston University Chobanian & Avedisian School of Medicine, Obstetrics, Education, Boston Medical Center, Health equity, Woman, Human, Black, SMPA, Boston University School of Public Health, Patient, SAN, Roivant Sciences, Uterine fibroid, Disease, Gynaecology, Mortality, BRCA, Fibroid, MPH, Breast cancer, Therapy, Empowerment, Nursing, Health

NEW YORK and SAN MATEO, Calif., June 26, 2023 /PRNewswire/ -- Today, Health in Her HUE ("HIHH"), a company dedicated to connecting Black women and women of color to culturally competent and sensitive healthcare providers, announced an ongoing collaboration with Myovant Sciences Ltd. ("Myovant"), soon to be Sumitomo Pharma America, Inc. ("SMPA") as a result of the combination announced April 2023. The collaboration will kick-off with a fireside chat titled "Fighting Fibroids Together: A Candid Conversation Over Brunch," in New Orleans, Louisiana on July 1st, 2023 during the ESSENCE festival weekend. In acknowledgement of Fibroid Awareness Month, this event aims to support education and awareness efforts for historically underserved populations diagnosed with uterine fibroids.

Key Points: 
  • The collaboration will kick-off with a fireside chat titled "Fighting Fibroids Together: A Candid Conversation Over Brunch," in New Orleans, Louisiana on July 1st, 2023 during the ESSENCE festival weekend.
  • In acknowledgement of Fibroid Awareness Month, this event aims to support education and awareness efforts for historically underserved populations diagnosed with uterine fibroids.
  • The event will help launch HIHH's new Fibroids-focused Care Squad , which focuses on guiding participants toward a better understanding of fibroids as a health relevant condition and the possible linkage between fibroids and other health diagnoses.
  • With a wealth of experience in fibroids, endometriosis, and disparities in maternal morbidity and mortality, Dr. Noel is a leading voice in women's health and developed the content for the Fibroids-focused Care Squad.

Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids

Retrieved on: 
Wednesday, May 17, 2023
Wearables, Mobile Technology, Technology, Women, Health Technology, Software, Consumer, Health, Data Management, Science, Other Science, Endometriosis, Pelvic inflammatory disease, Life, Education, Workplace, Absenteeism, Dysmenorrhea, Statistics, Innovation, Multimedia, Cycle, Interface (computing), Meigs's syndrome, Roivant Sciences, Uterine fibroid, Fibroid, Menstrual cycle, Diagnosis, Entrepreneurship, Ageing, Uterine cancer, Primary ovarian insufficiency, Ovarian cancer, Environment, Female, Nursing, Management, Medical device, Medical imaging, Birth control, Evidence-based policy

Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.

Key Points: 
  • Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.
  • View the full release here: https://www.businesswire.com/news/home/20230517005194/en/
    “At Myovant, we know that stigma can often keep people quiet about periods, leading to delayed care and increased discomfort.
  • It also contributes to the lack of awareness about how conditions such as endometriosis and uterine fibroids can increase absenteeism and impact performance at work and school,” said Kalahn Taylor-Clark, vice president and head of Strategic Partnerships and Innovation at Myovant Sciences.
  • The survey covered four areas, including demographics, menstrual history and health, experiences at work or school, and experiences with medical providers.

La Jolla Vein & Vascular Celebrates Opening of New Clinic in North County San Diego

Retrieved on: 
Thursday, May 11, 2023
Managed Care, Radiology, Health, Surgery, Lymphedema, Osteoarthritis, Interventional radiology, Rancho Santa Fe, California, Amputation, Varicose veins, PAD, Ageing, Multimedia, Municipal council, Varicocele, Moyamoya disease, De Young, Arusha City Council, Patient, Physician, Swelling, Uterine fibroid, Deep vein thrombosis, Diagnosis, GAE, May–Thurner syndrome, Commerce, Pelvic congestion syndrome, Medical imaging

La Jolla Vein & Vascular held a ribbon cutting and open house this week to celebrate the newly opened Vein Clinic and Endovascular Center.

Key Points: 
  • La Jolla Vein & Vascular held a ribbon cutting and open house this week to celebrate the newly opened Vein Clinic and Endovascular Center.
  • View the full release here: https://www.businesswire.com/news/home/20230511005703/en/
    Dr. Nisha Bunke (with scissors) kicks off the ribbon cutting ceremony to celebrate the opening of La Jolla Vein & Vascular's new medical clinic in Vista, California on May 9th, 2023.
  • “This new clinic was created to offer greater support for patients who need specialized vascular care,” said Dr. Nisha Bunke, Medical Director of La Jolla Vein & Vascular.
  • “Our first office in La Jolla was established in 2010, where many of our patients drive long distances to receive care.

Virtuoso Surgical Unveils Design of Groundbreaking Robotic Surgery System

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Surgery, Health, Medical Devices, Robotics, Hospitals, Health Technology, Technology, ENT, Financial Industry Regulatory Authority, Surgeon, Ear, Elective surgery, BPH, Cadaver, VISE, Bladder cancer, Endoscopy, Doctor of Philosophy, Gynaecology, Sale, Nose, Traction, Neurosurgery, Physician, Uterine fibroid, FACS, Entrepreneurship, Lead (engineering), FDA, III, Urology, Dentistry, Medical device, Engineering, MD

Nashville-based medical device company Virtuoso Surgical, Inc. has unveiled its revolutionary robotic surgery system .

Key Points: 
  • Nashville-based medical device company Virtuoso Surgical, Inc. has unveiled its revolutionary robotic surgery system .
  • “These are groundbreaking maneuvers in endoscopic/endoluminal surgery that are not possible with today’s instruments.”
    The unveiling of the product marks the end of the design stage for Virtuoso Surgical and progress in the regulatory phase.
  • They developed the Virtuoso Surgical system with a design team helmed by COO and Lead Engineer Richard Hendrick, PhD.
  • “Our team set out to bring the stability and dexterity of robotic surgery to the rigid endoscopy space, and we have achieved that with the Virtuoso Surgical system ,” Richard Hendrick, PhD , said.

CCRM Fertility Adds Dr. Sina Abhari to its Orange County Physician Team

Retrieved on: 
Wednesday, May 3, 2023
Emory University, Endometriosis, Avicenna International College, Infertility, Ovarian reserve, Research, Fertilisation, Gynaecology, Reproductive biology, Science, Suite, Fertility, American Society for Reproductive Medicine, Publication, Johns Hopkins University, Patient, Physician, Uterine fibroid, Michigan State University, Obstetrics, ASRM, Reproductive medicine, Health, Society, Birth control, Endocrinology

NEWPORT BEACH, Calif., May 3, 2023 /PRNewswire/ -- CCRM Fertility, the global pioneer in fertility treatment, research and science, welcomes Dr. Sina Abhari to its team of physicians in Newport Beach, Calif. Dr. Abhari is a reproductive endocrinology and infertility specialist who is board-certified in obstetrics and gynecology and board-eligible in reproductive endocrinology and infertility. He joins CCRM Fertility as medical director after coming from Johns Hopkins University as an assistant professor and specialist in reproductive endocrinology and infertility. Dr. Abhari is currently accepting new patients.

Key Points: 
  • He joins CCRM Fertility as medical director after coming from Johns Hopkins University as an assistant professor and specialist in reproductive endocrinology and infertility.
  • "There is an increasing need for high-quality fertility treatments, with approximately one in six people experiencing infertility at some stage in their lives," said CCRM Fertility CEO Bob LaGalia.
  • "With the addition of Dr. Abhari to our Orange County team, we can help even more individuals and couples grow their families with compassionate and innovative fertility care."
  • CCRM Fertility of Orange County is located at: 3501 Jamboree, Suite 1100, Newport Beach, CA 92660.

Gameto Expands Executive Team with the Addition of Teri Loxam as Chief Financial Officer

Retrieved on: 
Friday, April 28, 2023
University, Therapy, University of California, Irvine Medical Center, Head, Biotechnology, Infection, TMT, Cancer, Woman, Infertility, IMAX Corporation, MBA, Bristol Myers Squibb, IVF, University of Victoria, Acquisition, Physician, Uterine fibroid, CFO, Knowledge, Merck, Health, SQZ, Female, Management, Pharmaceutical industry, Arnold Loxam, EU, Biology, Serono

NEW YORK, April 28, 2023 /PRNewswire/ -- Gameto, a female-led biotech company developing therapies to improve the female reproductive journey, today announced the expansion of its executive team with the appointment of Teri Loxam as its first Chief Financial Officer. In this new role, Teri will oversee Gameto's financial function, as well as play a key role in overall company strategy.

Key Points: 
  • NEW YORK, April 28, 2023 /PRNewswire/ -- Gameto, a female-led biotech company developing therapies to improve the female reproductive journey, today announced the expansion of its executive team with the appointment of Teri Loxam as its first Chief Financial Officer.
  • In this new role, Teri will oversee Gameto's financial function, as well as play a key role in overall company strategy.
  • Prior to joining Gameto, Teri was Chief Operating Officer & Chief Financial Officer at Kira Pharmaceuticals, a clinical-stage biotech company developing transformative therapies for people with complement-mediated diseases.
  • "Gameto's highly innovative platform and dedication to improve and support women's health is impressive," said Teri Loxam, Chief Financial Officer of Gameto.

Uterine Fibroids Impact Up to 70% of African American Women Over the Age of 50

Retrieved on: 
Saturday, April 15, 2023
Pelvic pain, Advertising, Pregnancy, Bleeding, Wrist, Friends, Patient, Neoplasm, Urination, Quality of life, Constipation, Nutrient, Woman, Infertility, Research, Uterus, Weight gain, Precision, Pain, Blood, Fibroid, MD, Iron, National Institute for Health and Care Excellence, Risk, Physiology, Menstruation, Uterine fibroid, Uterine artery embolization, Personal lubricant, Hysterectomy, UFE, Groin, Family, Sand, Urinary incontinence, Birth control

San Diego, April 15, 2023 /PRNewswire-PRWeb/ -- Precision Therapy provides outpatient fibroid treatment in San Diego to host virtual event!

Key Points: 
  • Up to 40% of women over the age of 35 have uterine fibroids, and that number increases to over 70% of women over 50.
  • African American women are three times more likely to have fibroids than women of other ethnicities.
  • Up to 40% of women over the age of 35 have uterine fibroids, and that number increases to over 70% of women over 50.
  • African American women are three times more likely to have fibroids than women of other ethnicities.

Gynesonics Names Industry Veteran Skip Baldino President and CEO, Announces $25M Financing to Expand Worldwide Commercialization

Retrieved on: 
Tuesday, April 11, 2023
Transoral incisionless fundoplication, Given Imaging, Abbott, Abbott Laboratories, Woman, Sale, Regenerative medicine, Calumet Specialty Products Partners, GERD, ACell, Uterine fibroid, Hospital Productions, Growth, Gastroesophageal reflux disease, Hospira, Health, EGS, Covidien, Pharmaceutical industry, Nursing

Mr. Baldino, who will also serve as member of the Board of Directors, succeeds Christopher Owens.

Key Points: 
  • Mr. Baldino, who will also serve as member of the Board of Directors, succeeds Christopher Owens.
  • Gynesonics is also pleased to announce that the company has closed on a significant financing of $25M to help further drive the growth and adoption of the Sonata® System.
  • Mr. Baldino has over 35 years of healthcare experience in both private start-ups and large public companies.
  • “I am excited to join the Gynesonics team at this pivotal point in the company’s commercial evolution,” said Mr. Baldino.

SIR Foundation Receives Major Gift to Support Research Grants and Panel on Uterine Health

Retrieved on: 
Monday, March 6, 2023
MD, Physician, Society of Interventional Radiology, Uterine fibroid, UFE, Adenomyosis, Research, Uterine artery embolization, Woman, Patient, Collection, Society, SIR, Knowledge, Interventional radiology, Pharmaceutical industry, Medical device

PHOENIX, March 6, 2023 /PRNewswire/ -- The Society of Interventional Radiology (SIR) Foundation announced a major gift from John Lipman, MD, FSIR, of Atlanta, that will propel uterine fibroid research forward.

Key Points: 
  • PHOENIX, March 6, 2023 /PRNewswire/ -- The Society of Interventional Radiology (SIR) Foundation announced a major gift from John Lipman, MD, FSIR, of Atlanta, that will propel uterine fibroid research forward.
  • The announcement was made at the SIR Foundation Gala on March 5 during the SIR 2023 Annual Scientific Meeting.
  • The Dr. Scott C. Goodwin Uterine Artery Embolization Grant is focused on advancing uterine fibroid and uterine artery embolization research and will launch in October 2023.
  • Spies, MD, FSIR, are highly regarded pioneers of uterine fibroid research, having led the SIR Foundation's Fibroid Registry, the largest collection of data on uterine fibroids, and conducted foundational research into uterine artery embolization.